| Literature DB >> 32164495 |
Renan C Castello-Branco1, Thiago Cerqueira-Silva1, Alisson L Andrade1, Beatriz M M Gonçalves1, Camila B Pereira1, Iuri F Felix1, Leila S B Santos1, Louise M Porto1, Maria E L Marques1, Marilia B Catto1, Murilo A Oliveira1, Paulo R S P de Sousa1, Pedro J R Muiños1, Renata M Maia1, Saul Schnitman1, Jamary Oliveira-Filho1.
Abstract
Background Obstructive sleep apnea (OSA) is present in 60% to 70% of stroke patients. Cerebral vasoreactivity in patients with stroke and OSA has not been well studied and could identify a new pathophysiologic mechanism with potential therapeutic intervention. We aimed to determine whether risk categories for OSA are associated with cerebral vasoreactivity in stroke patients. Methods and Results In this cross-sectional study of a cohort of patients with stroke, we used clinical questionnaires (Sleep Obstructive Apnea Score Optimized for Stroke [SOS] and snoring, tiredness, observed, pressure, bmi, age, neck, gender [STOP-BANG] scores) to assess the risk of OSA and transcranial Doppler to assess cerebral vasoreactivity (breath-holding index and visual evoked flow velocity response). Of the 99 patients included, 77 (78%) had medium or high risk of OSA and 80 performed transcranial Doppler. Mean breath-holding index was 0.52±0.37, and median visual evoked flow velocity response was 10.8% (interquartile range: 8.8-14.5); 54 of 78 (69%) showed impaired anterior circulation vasoreactivity (breath-holding index <0.69) and 53 of 71 (75%) showed impaired posterior circulation vasoreactivity (visual evoked flow velocity response ≤14.0%). There was a significant negative correlation between the risk of OSA calculated by STOP-BANG and the breath-holding index (rS=-0.284, P=0.012). The following variables were associated with low anterior circulation vasoreactivity: dyslipidemia (odds ratio: 4.7; 95% CI, 1.5-14.2) and STOP-BANG score (odds ratio: 1.7 per 1-point increase; 95% CI, 1.1-1.5). Conclusions A high risk of OSA and impaired vasoreactivity exists in the population that has had stroke. Dyslipidemia and STOP-BANG sleep apnea risk categories were independently associated with impaired anterior circulation vasoreactivity.Entities:
Keywords: cerebral vasoreactivity; obstructive sleep apnea; stroke; transcranial Doppler; ultrasonography
Mesh:
Year: 2020 PMID: 32164495 PMCID: PMC7335520 DOI: 10.1161/JAHA.119.015313
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Univariable Analyses Comparing Stroke Patients With Normal or Abnormal Anterior Circulation Vasoreactivity
| Variable | All Patients (N=78 | Normal Anterior Vasoreactivity (n=24) | Abnormal Anterior Vasoreactivity (n=54) |
|
|---|---|---|---|---|
| Age, y, mean±SD | 57±13 | 52±16 | 60±11 | 0.019 |
| Female sex, n (%) | 39 (50) | 13 (57) | 26 (47) | 0.456 |
| BMI, mean±SD | 26±4.5 | 25.7±5.7 | 25.9±3.9 | 0.868 |
| Alcohol use, n (%) | 16 (20) | 4 (17) | 12 (22) | 0.659 |
| Smoking, n (%) | 16 (20) | 5 (22) | 11 (20) | 0.862 |
| Hypertension, n (%) | 60 (77) | 13 (56) | 47 (85) | 0.006 |
| Diabetes mellitus, n (%) | 25 (32) | 5 (22) | 20 (36) | 0.207 |
| Dyslipidemia, n (%) | 50 (64) | 8 (35) | 42 (76) | <0.001 |
| Coronary artery disease, n (%) | 9 (11) | 1 (4) | 8 (14) | 0.199 |
| Peripheral obstructive arterial disease, n (%) | 2 (3) | 0 (0) | 2 (4) | 0.354 |
| Heart failure, n (%) | 16 (20) | 4 (17) | 12 (22) | 0.659 |
| Atrial fibrillation, n (%) | 10 (13) | 4 (17) | 6 (11) | 0.435 |
| Chronic kidney disease, n (%) | 4 (5) | 1 (4) | 3 (5) | 0.840 |
| Hemorrhagic stroke, n (%) | 12 (15) | 6 (26) | 6 (11) | 0.090 |
| Vascular territory, n (%) | ||||
| Anterior circulation | 42 (78) | 10 (77) | 32 (78) | 0.932 |
| Posterior circulation | 12 (22) | 3 (23) | 9 (22) | |
| Stroke etiology, n (%) | 0.801 | |||
| Large‐vessel atherothrombosis | 2 (3) | 1 (7) | 1 (2) | |
| Small‐vessel occlusion (lacune) | 3 (5) | 0 (0) | 3 (7) | |
| Cardioembolic | 19 (32) | 6 (40) | 13 (29) | |
| Other known etiologies | 2 (3) | 0 (0) | 2 (4) | |
| Cryptogenic | 8 (14) | 2 (13) | 6 (14) | |
| >1 Cause | 1 (2) | 0 (0) | 1 (2) | |
| Incomplete investigation | 24 (41) | 6 (40) | 18 (41) | |
| Time from stroke onset to TCD, d, mean±SD | 423±174 | 428±212 | 415±158 | 0.801 |
| No. of coffee drinks per day, median (IQR) | 2 (0–4) | 2 (0–4) | 2 (0–4) | 0.965 |
| Medications in use, n (%) | ||||
| β‐Blocker | 16 (26) | 3 (13) | 13 (24) | 0.291 |
| CCB | 13 (17) | 1 (4) | 12 (22) | 0.059 |
| ACEI | 2 (3) | 0 (0) | 2 (4) | 0.354 |
| ARB | 25 (32) | 6 (26) | 19 (34) | 0.465 |
| Diuretic | 14 (18) | 2 (9) | 12 (22) | 0.168 |
| Aspirin | 19 (24) | 6 (26) | 13 (24) | 0.818 |
| Statin | 32 (41) | 11 (48) | 21 (38) | 0.430 |
| STOP‐BANG score, median (IQR) | 4 (2–5) | 2 (2–4) | 4 (3–5) | 0.002 |
| Low risk, n (%) | 24 (31) | 15 (65) | 9 (16) | <0.001 |
| Moderate risk, n (%) | 33 (42) | 4 (17) | 29 (53) | |
| High risk, n (%) | 21 (27) | 4 (17) | 17 (31) | |
| SOS score, mean±SD | 14.8±7.1 | 14.1±7.8 | 15.6±6.6 | 0.373 |
| Low risk, n (%) | 21 (27) | 9 (39) | 12 (22) | 0.207 |
| Moderate risk, n (%) | 38 (49) | 8 (35) | 30 (54) | |
| High risk, n (%) | 19 (24) | 6 (26) | 13 (25) | |
Abnormal anterior circulation vasoreactivity was defined as a breath‐holding index <0.69. SOS and STOP‐BANG are sleep apnea risk scores. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; IQR, interquartile range; and TCD, transcranial Doppler.
Two patients had insufficient bone window for insonation.
Figure 1Analysis of the risk of sleep apnea ( The black bars represent the 25th, 50th, and 75th percentiles.
Univariable Analyses Comparing Stroke Patients With Normal or Abnormal Posterior Circulation Vasoreactivity (N=71a)
| Variable | Normal Posterior Vasoreactivity (n=18) | Abnormal Posterior Vasoreactivity (n=53) |
|
|---|---|---|---|
| Age, y, mean±SD | 56±12 | 58±13 | 0.574 |
| Female sex, n (%) | 8 (44) | 25 (43) | 0.841 |
| BMI, mean±SD | 24±4.3 | 26±4.6 | 0.102 |
| Alcohol use, n (%) | 5 (29) | 10 (19) | 0.424 |
| Smoking, n (%) | 3 (17) | 13 (24) | 0.490 |
| Hypertension, n (%) | 12 (67) | 42 (79) | 0.280 |
| Diabetes mellitus, n (%) | 5 (28) | 18 (34) | 0.628 |
| Dyslipidemia, n (%) | 9 (50) | 37 (70) | 0.128 |
| Coronary artery disease, n (%) | 1 (6) | 7 (13) | 0.403 |
| Peripheral obstructive arterial disease, n (%) | 0 (0) | 2 (4) | 0.538 |
| Heart failure, n (%) | 5 (28) | 11 (21) | 0.538 |
| Atrial fibrillation, n (%) | 3 (17) | 6 (11) | 0.556 |
| Chronic kidney disease, n (%) | 0 (0) | 4 (7) | 0.230 |
| Hemorrhagic stroke, n (%) | 4 (22) | 7 (13) | 0.361 |
| Vascular territory | 0.682 | ||
| Anterior circulation | 8 (80%) | 28 (74%) | |
| Posterior circulation | 2 (20%) | 10 (26%) | |
| Ischemic stroke etiology, n (%) | 0.389 | ||
| Large‐vessel atherothrombosis | 2 (5) | 0 (0) | |
| Small‐vessel occlusion (lacune) | 1 (2) | 2 (18) | |
| Cardioembolic | 5 (45) | 13 (31) | |
| Other known etiologies | 0 (0) | 2 (5) | |
| Cryptogenic | 1 (9) | 7 (17) | |
| >1 Cause | 0 (0) | 1 (2) | |
| Incomplete investigation | 3 (27) | 16 (38) | |
| Time from stroke onset to TCD, d, mean±SD | 439±184 | 410±174 | 0.581 |
| Vasodilators | 0 (0%) | 3 (6%) | 0.302 |
| Sleep‐inducing medications | 0 (0%) | 9 (17%) | 0.061 |
| No. of coffee drinks per day, median (IQR) | 2 (0–4) | 2 (1–2) | 0.937 |
| Medications in use, n (%) | |||
| β‐Blocker | 2 (11) | 9 (17) | 0.552 |
| CCB | 2 (11) | 8 (15) | 0.675 |
| ACEI | 0 (0) | 2 (4) | 0.403 |
| ARB | 2 (11) | 22 (41) | 0.018 |
| Diuretic | 1 (6) | 12 (23) | 0.104 |
| Aspirin | 4 (22) | 12 (23) | 0.404 |
| Statin | 4 (33) | 23 (43) | 0.453 |
| SOS score, mean±SD | 13.2±5.6 | 15.8±7.1 | 0.167 |
| Low risk, n (%) | 5 (28) | 13 (24) | 0.704 |
| Moderate risk, n (%) | 10 (56) | 26 (49) | |
| High risk, n (%) | 3 (17) | 14 (26) | |
| STOP‐BANG, median (IQR) | 4 (2–5) | 4 (2–5) | 0.646 |
| Low risk, n (%) | 6 (33) | 16 (30) | 0.965 |
| Moderate risk, n (%) | 7 (39) | 21 (40) | |
| High risk, n (%) | 5 (28) | 16 (30) | |
Abnormal posterior circulation vasoreactivity defined as visual evoked flow velocity response ≤14.0%. SOS and STOP‐BANG are scores used to estimate sleep apnea risk. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; IQR, interquartile range; and TCD, transcranial Doppler.
Nine patients had insufficient bone window for insonation.
Multivariable Logistic Regression Showing Variables Associated With Impaired Anterior Circulation Vasoreactivity (Breath Holding Index <0.69)
| Variable | Odds Ratio | 95% CI |
|
|---|---|---|---|
| Dyslipidemia | 4.7 if present | 1.5–14.2 | 0.007 |
| STOP‐BANG score | 1.7 per 1‐point increase | 1.1–2.5 | 0.015 |
| Age | 1.0 per increased year | 0.9–1.05 | 0.956 |
| Female sex | 1.1 | 0.3–3.7 | 0.904 |
Total cholesterol ≥200 mg/dL, LDL (low‐density lipoprotein) ≥160 mg/dL, HDL (high‐density lipoprotein) <40 mg/dL for women or <50 mg/dL for men, triglycerides ≥150 mg/dL, use of cholesterol‐ or triglyceride‐lowering medications.24